Advertisement

N-methyl-d-aspartate Partial Agonist Enhanced Intensive Cognitive-Behavioral Therapy of Panic Disorder in Adolescents

  • Ovsanna Leyfer
  • Aubrey Carpenter
  • Donna Pincus
Original Article
  • 35 Downloads

Abstract

Panic disorder (PD) can result in significant functional impairment. Studies of cognitive behavioral therapy (CBT) for PD have demonstrated response rates ranging between 38 and 65%. d-cycloserine (DCS), a partial NMDA agonist, may enhance the effects of exposure-based therapy for PD in adults; however, no studies have examined its effect in adolescents with PD. This study examined the feasibility and acceptability of the use of DCS to augment intensive CBT for PD in adolescents. Twenty-four adolescents (ages 12–17) participated in this randomized, double-blinded, placebo-controlled trial, to compare CBT + DCS to CBT + placebo. The results demonstrated the feasibility and acceptability of the treatment to participants. No significant differences were found between the two groups, but both groups showed significant improvement. This is the first investigation of DCS in the treatment of PD in adolescents and it provides initial support for a more extensive study of DCS augmentation of CBT among adolescents with PD.

Keywords

Anxiety Panic disorder d-Cycloserine Cognitive-behavioral therapy Adolescents Outcome 

Notes

Funding

This study was funded by the Brain and Behavior Research Foundation Grant No. 19050 to Ovsanna Leyfer, Ph.D.

References

  1. 1.
    Barlow DH (2001) Anxiety and its disorders: the nature and treatment of anxiety and panic. Guilford Press, New YorkGoogle Scholar
  2. 2.
    Merikangas KR, He J-P, Burstein M et al (2010) Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication-Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry 49:980–989.  https://doi.org/10.1016/j.jaac.2010.05.017 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Lipsitz JD, Gur M, Sonnet FM et al (2010) Psychopathology and disability in children with unexplained chest pain presenting to the pediatric emergency department. Pediatr Emerg Care 26:830–836.  https://doi.org/10.1097/PEC.0b013e3181fb0e23 CrossRefPubMedGoogle Scholar
  4. 4.
    Batelaan N, Smit F, Graaf R et al (2007) Economic costs of full-blown and subthreshold panic disorder. J Affect Disord 104:127–136.  https://doi.org/10.1016/j.jad.2007.03.013 CrossRefPubMedGoogle Scholar
  5. 5.
    Ollendick T, Pincus D (2008) Panic disorder in adolescents. In: RG Steele, TD Elkin, M Roberts (eds) Handbook of evidence based therapies for children and adolescents. Springer, New York, pp 83–102CrossRefGoogle Scholar
  6. 6.
    Mattis SG, Pincus DB (2003) Treatment of SAD and panic disorder in children and adolescents. In: PM Barrett, TH Ollendick (eds) Handbook of interventions that work with children and adolescents: prevention and treatment. Wiley, West Sussex, pp 145–169Google Scholar
  7. 7.
    Woodward LJ, Fergusson DM (2001) Life course outcomes of young people with anxiety disorders in adolescence. J Am Acad Child Adolesc Psychiatry 40:1086–1093.  https://doi.org/10.1097/00004583-200109000-00018 CrossRefPubMedGoogle Scholar
  8. 8.
    Bittner A, Egger HL, Erkanli A et al (2007) What do childhood anxiety disorders predict? J Child Psychol Psychiatry Allied Discip 48:1174–1183.  https://doi.org/10.1111/j.1469-7610.2007.01812.x CrossRefGoogle Scholar
  9. 9.
    Gloster AT, Hauke C, Höfler M et al (2013) Long-term stability of cognitive behavioral therapy effects for panic disorder with agoraphobia: a two-year follow-up study. Behav Res Ther 51:830–839.  https://doi.org/10.1016/j.brat.2013.09.009 CrossRefPubMedGoogle Scholar
  10. 10.
    Hendriks G-J, Kampman M, Keijsers GPJ et al (2014) Cognitive-behavioral therapy for panic disorder with agoraphobia in older people: a comparison with younger patients. Depress Anxiety 31:669–677CrossRefPubMedGoogle Scholar
  11. 11.
    Roshanaei-Moghaddam B, Pauly MC, Atkins DC et al (2011) Relative effects of CBT and pharmacotherapy in depression versus anxiety: is medication somewhat better for depression, and CBT somewhat better for anxiety?. Depress Anxiety 28:560–567CrossRefPubMedGoogle Scholar
  12. 12.
    Pincus DB, May JE, Whitton SW et al (2010) Cognitive-behavioral treatment of panic disorder in adolescence. J Clin Child Adolesc Psychol 39:638–649.  https://doi.org/10.1080/15374416.2010.501288 CrossRefPubMedGoogle Scholar
  13. 13.
    Barlow DH, Gorman JM, Shear MK, Woods SW (2000) Cognitive-behavioral therapy, imipramine, or their combination for panic disorder. JAMA 283:2529.  https://doi.org/10.1001/jama.283.19.2529 CrossRefPubMedGoogle Scholar
  14. 14.
    Craske MG, Maidenberg E, Bystritsky A (1995) Brief cognitive-behavioral versus nondirective therapy for panic disorder. J Behav Ther Exp Psychiatry 26:113–120.  https://doi.org/10.1016/0005-7916(95)00003-I CrossRefPubMedGoogle Scholar
  15. 15.
    Milrod B, Chambless DL, Gallop R et al (2016) Psychotherapies for panic disorder: a tale of two sites. J Clin Psychiatry 77:927–935.  https://doi.org/10.4088/JCP.14m09507 CrossRefPubMedGoogle Scholar
  16. 16.
    Angelosante AG, Pincus DB, Whitton SW et al (2009) Implementation of an intensive treatment protocol for adolescents with panic disorder and agoraphobia. Cogn Behav Pract 16:345–357.  https://doi.org/10.1016/j.cbpra.2009.03.002 CrossRefGoogle Scholar
  17. 17.
    Elkins RM, Gallo KP, Pincus DB, Comer JS (2016) Moderators of intensive CBT for adolescent panic disorder: the role of fear and avoidance. Child Adolesc Ment Health 21:30–36.  https://doi.org/10.1111/camh.12122 CrossRefPubMedGoogle Scholar
  18. 18.
    Gallo KP, Cooper-Vince CE, Hardway CL et al (2014) Trajectories of change across outcomes in intensive treatment for adolescent panic disorder and agoraphobia. J Clin Child Adolesc Psychol 43:742–750.  https://doi.org/10.1080/15374416.2013.794701 CrossRefPubMedGoogle Scholar
  19. 19.
    Hardway CL, Pincus DB, Gallo KP, Comer JS (2015) Parental involvement in intensive treatment for adolescent panic disorder and its impact on depression. J Child Fam Stud 24:3306–3317.  https://doi.org/10.1007/s10826-015-0133-7 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Pincus DB, Elkins RM, Hardway C (2014) Intensive treatments for adolescent panic disorder and agoraphobia: helping youth move beyond avoidance. Psychopathol Rev 1:189–194CrossRefGoogle Scholar
  21. 21.
    Hofmann SG, Otto MW, Pollack MH, Smits JA (2012) D-Cycloserine as an augmentation strategy for cognitive behavioral therapy for anxiety disorders: an update. Curr Psychiatry Rep 18:5659–5662.  https://doi.org/10.2174/138161212803530916 Google Scholar
  22. 22.
    Norberg MM, Krystal JH, Tolin DF (2008) A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 63:1118–1126CrossRefPubMedGoogle Scholar
  23. 23.
    Rodrigues H, Figueira I, Lopes A et al (2014) Does d-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis. PLoS ONE 9:e93519CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Otto MW, Tolin DF, Simon NM et al (2010) Efficacy of D-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry 67:365–370.  https://doi.org/10.1016/j.biopsych.2009.07.036 CrossRefPubMedGoogle Scholar
  25. 25.
    Siegmund A, Golfels F, Finck C et al (2011) D-Cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. J Psychiatr Res 45:1042–1047.  https://doi.org/10.1016/j.jpsychires.2011.01.020 CrossRefPubMedGoogle Scholar
  26. 26.
    Onur OA, Schlaepfer TE, Kukolja J et al (2010) The N-methyl-D-aspartate receptor co-agonist D-cycloserine facilitates declarative learning and hippocampal activity in humans. Biol Psychiatry 67:1205–1211.  https://doi.org/10.1016/j.biopsych.2010.01.022 CrossRefPubMedGoogle Scholar
  27. 27.
    Storch EA, Murphy TK, Goodman WK et al (2010) A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry 68:1073–1076.  https://doi.org/10.1016/j.biopsych.2010.07.015 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Farrell LJ, Waters AM, Boschen MJ et al (2013) Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of d-cycloserine-augmented behavior therapy. Depress Anxiety 30:723–731.  https://doi.org/10.1002/da.22132 CrossRefPubMedGoogle Scholar
  29. 29.
    Scheeringa MS, Weems CF (2014) Randomized placebo-controlled D-cycloserine with cognitive behavior therapy for pediatric posttraumatic stress. J Child Adolesc Psychopharmacol 24:69–77.  https://doi.org/10.1089/cap.2013.0106 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Byrne SP, Rapee RM, Richardson R et al (2015) D-cycloserine enhances generalization of fear extinction in children. Depress Anxiety 32:408–414.  https://doi.org/10.1002/da.22356 CrossRefPubMedGoogle Scholar
  31. 31.
    Carpenter-Hyland EP, Chandler LJ (2007) Adaptive plasticity of NMDA receptors and dendritic spines: implications for enhanced vulnerability of the adolescent brain to alcohol addiction. Pharmacol Biochem Behav 86:200–208CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    George D, Mallery P, George D, Mallery P (2003) SPSS for Windows step by step: a simple guide and reference. 11.0 update, 4th edn. Allyn & Bacon, BostonGoogle Scholar
  33. 33.
    Silverman W, Albano AM (1996) Anxiety disorders interveiw schedule for DSM-IV. Graywind, New YorkGoogle Scholar
  34. 34.
    Katherine Shear M, Brown TA, Barlow DH et al (1997) Multicenter collaborative panic disorder severity scale. Am J Psychiatry 154:1571–1575.  https://doi.org/10.1176/ajp.154.11.1571 CrossRefGoogle Scholar
  35. 35.
    Shear MK, Rucci P, Williams J et al (2001) Reliability and validity of the Panic Disorder Severity Scale: replication and extension. J Psychiatr Res 35:293–296.  https://doi.org/10.1016/S0022-3956(01)00028-0 CrossRefPubMedGoogle Scholar
  36. 36.
    Elkins RM, Pincus DB, Comer JS (2014) A psychometric evaluation of the panic disorder severity scale for children and adolescents. Psychol Assess 26:609–618.  https://doi.org/10.1037/a0035283 CrossRefPubMedGoogle Scholar
  37. 37.
    Rapee RM, Craske MG, Brown TA, Barlow DH (1996) Measurement of perceived control over anxiety-related events. Behav Ther 27:279–293.  https://doi.org/10.1016/S0005-7894(96)80018-9 CrossRefGoogle Scholar
  38. 38.
    Hafner RJ, Marks IM (1976) Exposure in vivo of agoraphobics: contributions of diazepam, group exposure, and anxiety evocation. Psychol Med 6:71–88CrossRefPubMedGoogle Scholar
  39. 39.
    Silverman WK, Fleisig W, Rabian B, Peterson RA (1991) Childhood Anxiety Sensitivity Index. J Clin Child Psychol 20:162–168.  https://doi.org/10.1207/s15374424jccp2002 CrossRefGoogle Scholar
  40. 40.
    Peterson RA, Heilbronner RL (1987) The anxiety sensitivity index: construct validity and factor analytic structure. J Anxiety Disord 1:117–121.  https://doi.org/10.1016/0887-6185(87)90002-8 CrossRefGoogle Scholar
  41. 41.
    Silverman WK, Ginsburg GS, Goedhart AW (1999) Factor structure of the childhood anxiety sensitivity index. Behav Res Ther 37:903–917.  https://doi.org/10.1016/S0005-7967(98)00189-2 CrossRefPubMedGoogle Scholar
  42. 42.
    Chorpita BF, Albano AM, Barlow DH (1996) Child Anxiety Sensitivity Index: considerations for children with anxiety disorders. J Clin Child Psychol 25:77–82.  https://doi.org/10.1207/s15374424jccp2501_9 CrossRefGoogle Scholar
  43. 43.
    Chorpita BF, Daleiden EL (2000) Properties of the Childhood Anxiety Sensitivity Index in children with anxiety disorders: autonomic and nonautonomic factors. Behav Ther Ther 31:327–349.  https://doi.org/10.1016/S0005-7894(00)80018-0 CrossRefGoogle Scholar
  44. 44.
    Guy W (1976) The Clinical Global Impression Scale. In: ECDEU Assessment Manual for Psychopharmacology-Revised. US Dept. of Health, Education & Welfare, ADAMHA, NIMH Psychopharmacology Research Branch, Rockville, MD, pp 218–222Google Scholar
  45. 45.
    Mattis SG, Ollendick TH (1997) Panic in children and adolescents: a developmental analysis. Adv Clin Child Psychol 19:74Google Scholar
  46. 46.
    Gallo KP, Chan PT, Buzzella BA et al (2012) The impact of an 8-day intensive treatment for adolescent panic disorder and agoraphobia on comorbid diagnoses. Behav Ther 43:153–159.  https://doi.org/10.1016/j.beth.2011.05.002 CrossRefPubMedGoogle Scholar
  47. 47.
    Davis ML, Witcraft SM, Smits JAJ et al (2016) d-cycloserine augmentation of exposure therapy: review and new directions. Qual Prim Care 24 PS:30–32Google Scholar
  48. 48.
    Smits JAJ, Rosenfield D, Otto MW et al (2013) D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry.  https://doi.org/10.1016/j.biopsych.2012.12.009 PubMedCentralGoogle Scholar
  49. 49.
    Smits JAJ, Rosenfield D, Otto MW et al (2013) D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. J Psychiatr Res.  https://doi.org/10.1016/j.jpsychires.2013.06.020 PubMedCentralGoogle Scholar
  50. 50.
    Hofmann SG (2014) D-cycloserine for treating anxiety disorders: making good exposures better and bad exposures worse. Depress Anxiety 31:175–177CrossRefGoogle Scholar
  51. 51.
    Paul I, Nowak G, Layer RT et al (1994) Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther 269:95–102PubMedGoogle Scholar
  52. 52.
    McGuire JF, Wu MS, Piacentini J et al (2017) A meta-analysis of D-cycloserine in exposure-based treatment: moderators of treatment efficacy, response, and diagnostic remission. J Clin Psychiatry 78:196–206.  https://doi.org/10.4088/JCP.15r10334 CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Mataix-Cols D, Fernández de la Cruz L, Monzani B et al (2017) D-cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders. JAMA Psychiatry 74:501.  https://doi.org/10.1001/jamapsychiatry.2016.3955 CrossRefPubMedGoogle Scholar
  54. 54.
    Hofmann SG, Mundy EA, Curtiss J (2015) Neuroenhancement of exposure therapy in anxiety disorders. AIMS Neurosci.  https://doi.org/10.3934/Neuroscience.2015.3.123 PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Psychological and Brain Sciences, Center for Anxiety and Related DisordersBoston UniversityBostonUSA
  2. 2.Massachusetts General HospitalBostonUSA

Personalised recommendations